Overview: Varicella Zoster Qualitative PCR TestIntroduction: The Varicella Zoster Qualitative PCR Test detects VZV DNA to diagnose active infection, causing rash or pain. Aligned with 2023 CDC guidelines, it uses PCR for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected active VZV infection. Note: Test Parameters are not specified in input data; typically includes VZV DNA detection.
Other Names: VZV PCR Assay, Varicella Zoster DNA Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: VZV PCR testing began in the 1990s with viral diagnostic research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects VZV DNA to diagnose active chickenpox or shingles, guides treatment, and evaluates patients with rash or pain.
Test Parameters: Not specified in input data; typically includes VZV DNA detection.
Pretest Condition: No fasting required. Collect whole blood, serum, plasma, CSF, vesicle fluid, or saliva. Report history of rash, pain, or VZV exposure.
Specimen: Whole Blood (EDTA, 2-5 mL), Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL), CSF (sterile container, 1-2 mL), Vesicle Fluid (sterile container, 1-2 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document rash, pain, or history of VZV exposure. Include current medications, especially antivirals.
Consent: Written consent required, detailing the tests purpose, VZV infection implications, and risks of sample collection.
Procedural Considerations: Uses qualitative PCR to detect VZV DNA. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for active VZV diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Sample quality impacts specificity.
Clinical Significance: Positive VZV DNA confirms active infection, guiding antiviral therapy like acyclovir. Negative results may require IgM or repeat PCR.
Specialist Consultation: Consult an infectious disease specialist or dermatologist for result interpretation and treatment planning.
Additional Supporting Tests: VZV IgM, IgG, or clinical evaluation to confirm active VZV infection.
Test Limitations: Non-specific for infection stage; clinical correlation is needed. Sample quality affects sensitivity.
References: CDC VZV Guidelines, 2023; Clinical Infectious Diseases, Cohen JI, 2022.
